ArticleBlood advances2022
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- Trial
- Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.Bone marrow transplantation · 2026Review
- Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromes.Blood research · 2025Article
- Pandora's Box of AML: HowBiomedicines · 2025Review
- Article
- Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks.Cells · 2025Review
- IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.Discover oncology · 2025Article
- Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy.European journal of haematology · 2025Article
- Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.Haematologica · 2025Article
- Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older.Bone marrow transplantation · 2025Article
- The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.BMC pharmacology & toxicology · 2025Article
- Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.Bone marrow transplantation · 2024Article
- Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.Blood cancer journal · 2024Article
- Does the regional use of intensive chemotherapy impact the outcome of adults with AML?BMJ oncology · 2024Article
- Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.Bone marrow transplantation · 2024Article
- Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.Journal of personalized medicine · 2023Article
- Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.Haematologica · 2023Article
- Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.American journal of hematology · 2023Review
- Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.Blood cancer journal · 2023Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML) aged >60 years remains a matter of debate, notably when performed in first complete remission (CR1). To clarify this issue, the French Innovative Leukemia Organization (FILO) performed a 10-year real-world time-dependent analysis. The study enrolled patients between 60 and 70 years of age with AML in CR1 after intensive chemotherapy with intermediate (IR) or unfavorable (UR) risk according to the European LeukemiaNet (ELN) 2010 classification. The impact of allo-HSCT was analyzed through three models: (1) time-dependent Cox; (2) multistate for dynamic prediction; and (3) super landmark. The study enrolled 369 (73%) IR and 138 (27%) UR patients with AML, 203 of whom received an allo-HSCT. Classical multivariate analysis showed that allo-HSCT significantly improved relapse-free survival (RFS; hazard ratio [HR] [95% confidence interval (CI)], 0.47 [0.35-0.62]; P < .001) and overall survival (OS; HR [95% CI], 0.56 [0.42-0.76]; P < .001), independently of the ELN risk group. With the multistate model, the predicted 5-year probability for IR and UR patients to remain in CR1 without allo-HSCT was 8% and 1%, respectively. Dynamic predictions confirmed that patients without allo-HSCT continue to relapse over time. Finally, the super landmark model showed that allo-HSCT significantly improved RFS (HR [95% CI], 0.47 [0.36-0.62]; P < .001) and OS (HR [95% CI], 0.54 [0.40-0.72]; P < .001). allo-HSCT in CR1 is reported here as significantly improving the outcome of fit older patients with AML. Long-term RFS without allo-HSCT is very low (<10%), supporting allo-HSCT as being the best curative option for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.